Rare cancers About themeMore than 4 million people in the European Union are affected by rare cancers. Despite the rarity of each of these 186 cancers, they represent a total of about 22% of all cancer cases. This is more than any single common cancer. Rare cancers are identified as those with an incidence of less than 6 per 100,000 persons per year and include head and neck cancer, sarcoma, thyroid cancer, neuro-endocrine cancer, brain tumors, lymphoma and pediatric cancer. Unfortunately, the average outcome for patients with rare cancers is inferior to those with more common cancers.
Due to their low frequency, rare cancers pose particular challenges. Our mission therefore is to improve diagnosis and prognosis and to perform personalized clinical studies and translational bench-to-bedside research in patients with rare cancers. This will be performed in relationship with patient advocacy groups, if applicable. Given the rarity of these tumors, collaboration with national and international centers and partners is vital for the success of this theme.
- We aim to remedy late or incorrect diagnosis records.
- We aim to improve access to appropriate therapies and clinical expertise.
- We will raise the number of clinical trials in spite of the small number of patients.
- We will endeavor to raise market interests in the development of new therapies.
- We will seek to improve the number of available registries and tissue banks.